Italy Introduction In the phase III ELATIVE® trial (NCT04526665), the efficacy of elafibranor (a dual peroxisome proliferator-activated receptor-alpha/delta agonist) was assessed in patients with ...

This secondary analysis evaluated the effect of elafibranor on the lipid profiles of patients in ELATIVE®, who were divided into subgroups by concomitant lipid therapy. Methods In ELATIVE® ...

Meanwhile, Intercept Pharma’s obeticholic acid ... that elafibranor’s failure in NASH shouldn’t read through to its potential in PBC – a chronic, autoimmune disease in which bile ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts ... obeticholic acid – still a hopeful ...